One of the most serious health threats facing Americans today is the malady designated as obesity. There are 500 million Adults, a whopping 31 percent of the population, who are not simply overweight; they are classified as unable to enjoy optimum health and activity because of their weight.
The health risks most commonly linked to obesity are heart attack, stroke, high blood pressure, high cholesterol, and diabetes. The annual medical costs associated with these ills are astronomical. The risk of health issues are high for those who are overweight, however, when one is obese, the chance of risk rises exponentially.
Bio-pharmaceutical group, Vivus, has developed a product, in hope of rendering a solution to this pandemic problem. The Food and Drug Administration recently announced consent, for the once daily Medication, Qsymia, commonly known as the weight loss pill.
The significance is that this medication was approved by the FDA this year; while the FDA has been reluctant to approve any weight loss medications in the last ten years. The pills performance has been noteworthy. Qsymia is a combination drug, consisting of two drugs, which are known to have varying degree of effectiveness with obese patients. Together is seems to be quite the combination.
This weight loss drug among other things, is approved under strenuous clinical study. Patients were monitored while on Qsymia for 12 consecutive months. In one study, patients lost an average of 6.7 per cent of body weight, while in the other, patients lost an average of 8.9 per cent. Patients on the highest dosages reported significant body weight loss as high as 22 pounds.
Researchers have determined that Qsymia is so effective because it targets two completely separate areas that cause overeating. The drugs that comprise the weight loss pill are Topiramate and Phentermine. The former is an anti-consultant, which makes the patient feel more satisfied after a meal. The latter is an appetite suppressant.
Research also has shown that the continued weight loss helps control other health conditions. Patients and their physicians report over extended use, that blood pressure decreases, and diabetic therapy is significantly reduced. It is also reported that symptoms associated with sleep apnea are lessened.
Qsymia has been approved for use, but not unrestricted use. Current guidelines suggest that the drug only be prescribed for patient with a BMI (Body mass index) greater than 30. In other words, the drug is for those clinically revealed as obese. In addition, Physicians and clinics that administer the drug are advised to closely monitor the patients. Side effects include congenital disorder in infants, if taken by women who are pregnant.
Qsymia is proving to be one of the best tools in the struggle to overcome obesity and get America healthy again. The foremost physicians and weight loss clinics have responded by offering Qsymia as an option for their patients. Equilibrium weight loss and longevity clinics offer Qsymia as part of a comprehensive line of weight loss programs.
The health risks most commonly linked to obesity are heart attack, stroke, high blood pressure, high cholesterol, and diabetes. The annual medical costs associated with these ills are astronomical. The risk of health issues are high for those who are overweight, however, when one is obese, the chance of risk rises exponentially.
Bio-pharmaceutical group, Vivus, has developed a product, in hope of rendering a solution to this pandemic problem. The Food and Drug Administration recently announced consent, for the once daily Medication, Qsymia, commonly known as the weight loss pill.
The significance is that this medication was approved by the FDA this year; while the FDA has been reluctant to approve any weight loss medications in the last ten years. The pills performance has been noteworthy. Qsymia is a combination drug, consisting of two drugs, which are known to have varying degree of effectiveness with obese patients. Together is seems to be quite the combination.
This weight loss drug among other things, is approved under strenuous clinical study. Patients were monitored while on Qsymia for 12 consecutive months. In one study, patients lost an average of 6.7 per cent of body weight, while in the other, patients lost an average of 8.9 per cent. Patients on the highest dosages reported significant body weight loss as high as 22 pounds.
Researchers have determined that Qsymia is so effective because it targets two completely separate areas that cause overeating. The drugs that comprise the weight loss pill are Topiramate and Phentermine. The former is an anti-consultant, which makes the patient feel more satisfied after a meal. The latter is an appetite suppressant.
Research also has shown that the continued weight loss helps control other health conditions. Patients and their physicians report over extended use, that blood pressure decreases, and diabetic therapy is significantly reduced. It is also reported that symptoms associated with sleep apnea are lessened.
Qsymia has been approved for use, but not unrestricted use. Current guidelines suggest that the drug only be prescribed for patient with a BMI (Body mass index) greater than 30. In other words, the drug is for those clinically revealed as obese. In addition, Physicians and clinics that administer the drug are advised to closely monitor the patients. Side effects include congenital disorder in infants, if taken by women who are pregnant.
Qsymia is proving to be one of the best tools in the struggle to overcome obesity and get America healthy again. The foremost physicians and weight loss clinics have responded by offering Qsymia as an option for their patients. Equilibrium weight loss and longevity clinics offer Qsymia as part of a comprehensive line of weight loss programs.
About the Author:
Are you looking to find out if Qsymia Capsules are already available around you? We all will have to get a doctors approval to get the Qsymia Available
No comments:
Post a Comment